Everything comes in 3's - Another insider buy perhaps on all of this good news...
"Kadcyla utilizes ImmunoGen’s ADC technology and is already approved to treat patients with HER2-positive mBC who previously received trastuzumab and a taxane"- The Street 12/19
SO Only patients already treated with Herceptin (SC) can receive Kadcyla. This is a much different scenario from the one HALO would have faced if the Marianne trial showed a benefit for Kadcyla use.
Torley said we should have a lung cancer trial this Month - which makes me think Monday is Lungday- two Mondays left till 2015- great day for PR.
After Top-Seller Remicade: Analysis of J&J’s Future
BY DAVID J. PHILLIPS DECEMBER 03, 2013
Remicade (IV), which delivered almost $5.0 billion (23.8%) of the drug maker’s $20.8 billion in pharmaceutical revenue through September 2013, will likely face generic biosimilars in Europe and the U.S. come 2015 and 2018, respectively. Against the mise-en-scène shadowed with generic competition for Remicade, JNJ remains the U.S. leader in immunology sales – owning 27% of the $17.0 billion market through December 2012, according to EvaluatePharma.
The stakes are enormous for drugs that treat rheumatoid arthritis and other immune system disorders. Johnson & Johnson’s Remicade brought in more than $7 billion last year. AbbVie’s (ABBV) competing blockbuster Humira brought in $9.3 billion. Amgen’s (AMGN) Enbrel has sales of more than $8 billion.
In earlier articles, YCharts looked at J&J's ability to fight off generic challenges to Remicade.
(Insert MabThera or Herceptin wherever you read Remicade)
It's a good day to be long Halozyme. Then in 3 wks- 1/12 Embargo lift on ASCO GI abstracts- PegpH20 1b Final Data with Historic Progression Free and Overall Survival Numbers in Panc Ca 4b will become part of oncologic conversation, further increasing interest in Halozyme- a great day to be long. The PFS number- 7.3 mo is already reported with the interim Overall # of 529 d back in 9/13- but we know Greg frost said back in Nov 2013 that the Overall number was not mature. In addition to the reporting of the mature data, we should hear how long the last patient lived. There was a complete biochemical responder. Hence the reference to Final data.
IMGN Manufactures Kadcyla for Roche- also HALO rose 5% yesterday- I believe on Both the granting of Orphan status in the EU (more on that on another post) And the fact that a failure of Kadcyla in trial means its label will not be broadened- leaving more for Herceptin SC to defend against the onslaught of biosimilars- and more royalties for HALO. Of interest was the combination of generic Taxane and Herceptin did as well as 2 new planned wonder drugs- Kadcyla and Perjeta. Furthermore, Perjeta plus Herceptin did show benefit in the Cleopatra trials- again insuring Herceptin and its SC entity will be a part of Roche's armamentarium, generating HALO royalties in a greater way than thought 2 days ago- for YEARS to come.
Here's a FierceBio piece on the Great White Hope that Was Kadcyl:
With nod, Roche's Kadcyla should quickly become blockbuster
FDA approves highly anticipated treatment for late-stage breast cancer
February 22, 2013 | By Eric Palmer
At an earnings call last month, Roche ($RHHBY) CEO Severin Schwan crowed a bit about the Swiss company's future, pointing to drugs in the pipeline like its highly anticipated breast cancer treatment and potential blockbuster T-DM1. Today, the FDA gave approval to the drug, which will be marketed as Kadcyla, for patients with HER2-positive, late-stage (metastatic) breast cancer. The drug will have an estimated monthly cost of $9,800, or about $94,000 for a full course of treatments, Forbes reports. As FierceBiotech points out, forecasts have put peak sales of the breakthrough antibody drug conjugate at between $2 billion and $5 billion.
In 2013 Remicade- an IV drug for Rheumatoid Arthritis- generated a tremendous $8.9B in global sales-its patent is due to expire in most of EU in 2015 and in US in 2018." JNJ Facing a big loss turns to HALO Enhanze, as Roche did for #11 and #24 drugs on the 2013 Top 100 Drug list.
He needs to believe that I have a million handles when I have only one.when you and confused trader tell h to leave - that makes 3 of us -
Do either of you two have any helpful science to contribute? It Would be a first- If Not - why don't you hold the door for each other and yes - leave. I have no connection to confused trader, but I totally agree with him.
Thank you for the kind words. I called him out early on one of his pompous tirades against me in which he declared authoritatively that a patient in 202 by definition could not have low hyaluronan content.
There is no hyaluronan screening in 202.
What a horrible short- bring back Fgnoms- some intelligence- this guy is a jock sniffing fast twitch ignoramus
J&J is NOT going to let Roche corner this market- Subcut means faster less costly therapy- favored by NICE, NHS and future 3rd Party Payers.
Janssen has a huge pipeline- Onc and Neuro especially- pleanty to keep funding PegpH20 trials for years to come!
.Yes So CFO was On time after all- Gave himself some wiggle room but came up with ANOTHER First Class Collaboration ! One two punch on target for 1/12 ASCO Embargo end...then 2015 the year of the compassioonate halt (on efficacy)
"In trading on Monday, shares of Halozyme Therapeutics Inc (HALO) entered into oversold territory, hitting an RSI reading of 29.3, after changing hands as low as $7.69 per share. By comparison, the current RSI reading of the S&P 500 ETF (SPY) is 35.7. A bullish investor could look at HALO's 29.3 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side"
There is so much data on early study 202 patients that the CEO alluded to at Oppenheimer but that she can't tell us about- people who got "many cycles" of pegph20-gem- are they still alive a year later? Has their disease progressed? I look for clues- like why would they be laaunching lung with a preannouncement on Anti PD-L1 if there wasn't data from early 202 that supported the small sampling record data from 201? The PR dept can't say a word about what's truly important. The MabThera SC-Revlimid study I found is nice but, again, it's all about PegpH20.